☆ 4.7 Article

Nasopharyngeal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

ANNALS OF ONCOLOGY (2009)

Journal

ANNALS OF ONCOLOGY

Volume 20, Issue -, Pages 123-125

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdp150

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

S. J. Strauss, A. M. Frezza, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J. Y. Blay, S. Bolle, S. Bonvalot, I Boukovinas, J. V. M. G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. de Alava, A. P. Dei Tos, X. Garcia Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V Ferraresi, A. Ferrari, N. Gaspar, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, A. Gronchi, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A. B. Miah, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M. A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A. A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, K. Sundby Hall, A. Trama, M. Unk, M. A. J. van de Sande, W. T. A. van der Graaf, W. J. van Houdt, T. Frebourg, R. Ladenstein, P. G. Casali, S. Stacchiotti

Summary: The paragraph lists the names of various researchers, possibly in the author list of a research paper.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

S. Koppikar, A. Oaknin, K. Govind Babu, D. Lorusso, S. Gupta, L. -Y. Wu, W. Rajabto, K. Harano, S. -h. Hong, R. A. Malik, H. Strebel, I. M. Aggarwal, C. -H. Lai, T. Dejthevaporn, S. Tangjitgamol, W. F. Cheng, W. Y. Chay, D. Benavides, N. M. Hashim, Y. W. Moon, M. Yunokawa, T. D. Anggraeni, W. Wei, G. Curigliano, A. Maheshwari, U. Mahantshetty, S. Sheshadri, S. Peters, T. Yoshino, G. Pentheroudakis

Summary: The European Society for Medical Oncology (ESMO) published the most recent version of their guidelines for endometrial cancer in 2022. In order to account for variations in endometrial cancer management in Asia, a virtual meeting was held in July 2022 to adapt the ESMO guidelines. The guidelines represent the consensus opinion of Asian experts from various oncological societies. The aim is to provide guidance for the management of endometrial cancer in different regions of Asia, considering variations in clinical presentation, diagnostic practices, and access to treatment options.

ESMO OPEN (2023)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

R. Kanesvaran, E. Castro, A. Wong, K. Fizazi, M. L. K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Summary: To accommodate the specific requirements of prostate cancer treatment in Asia, a special meeting was convened by ESMO and SSO to revise the guidelines published in 2020. These guidelines represent the consensus opinions of prostate cancer treatment experts from Asian countries and aim to provide optimization and harmonization recommendations for the management of prostate cancer patients across different regions in Asia.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

T. Yoshino, A. Cervantes, H. Bando, E. Martinelli, E. Oki, R. -H. Xu, N. A. Mulansari, K. Govind Babu, M. A. Lee, C. K. Tan, G. Cornelio, D. Q. Chong, L. -T. Chen, S. Tanasanvimon, N. Prasongsook, K. -H. Yeh, C. Chua, M. D. Sacdalan, W. J. Sow (Jenson), S. T. Kim, R. T. Chacko, R. A. Syaiful, S. Z. Zhang, G. Curigliano, S. Mishima, Y. Nakamura, H. Ebi, Y. Sunakawa, M. Takahashi, E. Baba, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO Guidelines for metastatic colorectal cancer (mCRC) were adapted to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for Asian patients. The guidelines were developed by a panel of experts from Asian oncological societies, based on scientific evidence and independent of treatment practices and reimbursement decisions. The aim is to optimize and harmonize the management of mCRC across Asia, considering the differences in screening practices, molecular profiling, and drug approvals and reimbursement strategies.

ESMO OPEN (2023)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

R. Kanesvaran, C. Porta, A. Wong, T. Powles, Q. S. Ng, M. Schmidinger, D. Ye, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, G. S. Bhattacharyya, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Summary: The ESMO and SSO held a special virtual guidelines meeting in May 2021 to adapt the 2019 guidelines for renal cell carcinoma treatment to account for ethnic differences in Asian patients. Expert opinions from oncological societies in China, India, Japan, Korea, Malaysia, Singapore, and Taiwan were considered based on scientific evidence independent of current treatment practices and drug access restrictions in Asian countries.

ESMO OPEN (2021)

Add to Collection

Article Medicine, General & Internal

Anal Cancer-Diagnosis, Treatment and Follow-Up

Robert Siegel, Ricardo Niklas Werner, Stephan Koswig, Matthew Gaskins, Claus Roedel, Felix Aigner

Summary: The study provides detailed information on the development of the guidelines for the treatment of anal cancer. It recommends chemoradiotherapy as the standard treatment for stages II-III, with a suggestion against biopsy in complete clinical response. For stage IV anal cancer, there are only open recommendations, urging further research in this area.

DEUTSCHES ARZTEBLATT INTERNATIONAL (2021)

Add to Collection

Review Cell Biology

Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment Guidance

Omayma Mazouji, Abdelhak Ouhajjou, Roberto Incitti, Hicham Mansour

Summary: Colorectal cancer is one of the most common cancers globally, with solid biopsy being an essential guide for clinical management, but liquid biopsy has shown significant promise as an alternative tool in various CRC clinical applications, such as early detection, treatment decision-making, and monitoring treatment response.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

Tetsuhide Ito, Toshihiko Masui, Izumi Komoto, Ryuichiro Doi, Robert Y. Osamura, Akihiro Sakurai, Masafumi Ikeda, Koji Takano, Hisato Igarashi, Akira Shimatsu, Kazuhiko Nakamura, Yuji Nakamoto, Susumu Hijioka, Koji Morita, Yuichi Ishikawa, Nobuyuki Ohike, Atsuko Kasajima, Ryoji Kushima, Motohiro Kojima, Hironobu Sasano, Satoshi Hirano, Nobumasa Mizuno, Taku Aoki, Takeshi Aoki, Takao Ohtsuka, Tomoyuki Okumura, Yasutoshi Kimura, Atsushi Kudo, Tsuyoshi Konishi, Ippei Matsumoto, Noritoshi Kobayashi, Nao Fujimori, Yoshitaka Honma, Chigusa Morizane, Shinya Uchino, Kiyomi Horiuchi, Masanori Yamasaki, Jun Matsubayashi, Yuichi Sato, Masau Sekiguchi, Shinichi Abe, Takuji Okusaka, Mitsuhiro Kida, Wataru Kimura, Masao Tanaka, Yoshiyuki Majima, Robert T. Jensen, Koichi Hirata, Masayuki Imamura, Shinji Uemoto

Summary: Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical manifestations. Accurate pathological classification and determination of tumor characteristics are crucial for selecting appropriate treatment strategies. The revised Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) provide comprehensive directions for the management of NENs, incorporating new evidence and updated concepts.

JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Article Oncology

Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

B. Keam, J-P Machiels, H. R. Kim, L. Licitra, W. Golusinski, V Gregoire, Y. G. Lee, C. Belka, Y. Guo, S. J. Rajappa, M. Tahara, M. Azrif, M. K. Ang, M-H Yang, C-H Wang, Q. S. Ng, W. I. Wan Zamaniah, N. Kiyota, S. Babu, K. Yang, G. Curigliano, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis

Summary: ESMO and KSMO convened a special virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider potential ethnic differences in Asian patients' treatment of SCCs of the head and neck. These guidelines represent consensus opinions from experts across Asia and provide expert recommendations for the diagnosis, treatment, and management of patients with SCC of the oral cavity, larynx, oropharynx, and hypopharynx.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

S. -A. Im, A. Gennari, Y. H. Park, J. H. Kim, Z. -F. Jiang, S. Gupta, T. H. Fadjari, K. Tamura, M. Y. Mastura, M. L. T. Abesamis-Tiambeng, E. H. Lim, C. -H. Lin, A. Sookprasert, N. Parinyanitikul, L. -M. Tseng, S. -C. Lee, P. Caguioa, M. Singh, Y. Naito, R. A. Hukom, B. K. Smruti, S. -S. Wang, S. B. Kim, K. -H. Lee, H. K. Ahn, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis, G. Curigliano, N. Harbeck

Summary: The most recent version of the ESMO Clinical Practice Guidelines for metastatic breast cancer was published in 2021. In 2022, a special hybrid guidelines meeting was held to adapt these guidelines to the Asian context, with input from Asian oncology societies. The aim is to provide harmonized management of MBC patients across Asia.

ESMO OPEN (2023)

Add to Collection

Review Medicine, General & Internal

Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up

Clara Carnicer-Caceres, Jose Antonio Arranz-Amo, Cristina Cea-Arestin, Maria Camprodon-Gomez, David Moreno-Martinez, Sara Lucas-Del-Pozo, Marc Molto-Abad, Ariadna Tigri-Santina, Irene Agraz-Pamplona, Jose F. Rodriguez-Palomares, Jorge Hernandez-Vara, Mar Armengol-Bellapart, Mireia del-Toro-Riera, Guillem Pintos-Morell

Summary: Fabry disease is a lysosomal storage disorder caused by mutations in the GLA gene, leading to gradual accumulation of globotriaosylceramide in different tissues, which can induce multiorgan lesions, especially in the kidney, heart, and nervous system. Enzyme replacement therapy can delay disease progression, but early diagnosis remains a clinical challenge, prompting the search for biomarkers to detect and predict disease evolution.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Notification System for Overdue Radiology Recommendations Improves Rates of Follow-Up and Diagnosis

Jaimee Mannix, Justine LaVoye, Michael Wasserman, Nicholas E. Lada, Keita Onoue, Khalid Hassan, Rutuparna Sarangi, Samir Haroon, Aneesa Gaffar, Muhammad M. Qureshi, Avneesh Gupta

Summary: This study aimed to quantify improved rates of follow-up and additional important diagnoses made after notification for overdue workups recommended by radiologists. Results showed that notification of providers about overdue follow-up recommendations led to a reduction in incomplete follow-ups and yielded clinically important diagnoses.

AMERICAN JOURNAL OF ROENTGENOLOGY (2021)

Add to Collection

Article Oncology

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

Rosario Garcia-Campelo, Ivana Sullivan, Edurne Arriola, Amelia Insa, Oscar Juan Vidal, Patricia Cruz-Castellanos, Teresa Moran, Noemi Reguart, Jon Zugazagoitia, Manuel Domine

Summary: Small-cell lung cancer (SCLC) accounts for about 15% of lung cancers and is highly aggressive. Surgical resection followed by adjuvant therapy is curative for limited-stage SCLC, but only a minority of patients are eligible for surgery. Concurrent chemo-radiotherapy is the standard treatment for inoperable limited-stage SCLC, while combination chemotherapy with programmed death-ligand 1 inhibitors has become the new front-line standard for extensive-stage SCLC. Advances in understanding SCLC biology and new treatment approaches offer potential improvements in patient care.

CLINICAL & TRANSLATIONAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Adherence to Follow-up Testing Recommendations in US Veterans Screened for Lung Cancer, 2015-2019

Eduardo R. Nunez, Tanner J. Caverly, Sanqian Zhang, Mark E. Glickman, Shirley X. Qian, Jacqueline H. Boudreau, Christopher G. Slatore, Donald R. Miller, Renda Soylemez Wiener

Summary: This study found that less than two-thirds of veterans received timely recommended follow-up after initial lung cancer screening, with higher risk of delayed or absent follow-up among marginalized populations such as Black individuals, individuals with mental health disorders, and individuals with low income. Future work should focus on identifying facilities that promote high adherence and disseminating successful strategies to promote equity in lung cancer screening among marginalized populations.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

A. T. C. Chan, V. H. F. Lee, R-L Hong, M. -J. Ahn, W. Q. Chong, S. -B. Kim, G. F. Ho, P. B. Caguioa, N. Ngamphaiboon, C. Ho, M. A. S. A. Aziz, Q. S. Ng, C. -J. Yen, N. Soparattanapaisarn, R. K. -C Ngan, S. K. Kho, M. L. A. Tiambeng, T. Yun, V. Sriuranpong, A. P. Algazi, A. Cheng, E. Massarelli, R. F. Swaby, S. Saraf, J. Yuan, L. L. Siu

Summary: Pembrolizumab showed robust antitumor activity and manageable safety in patients with platinum-pretreated recurrent and/or metastatic nasopharyngeal carcinoma. However, it did not significantly improve overall survival compared with chemotherapy.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Oncology

Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions

W. K. Jacky Lam, Ann D. King, Jacob A. Miller, Zhiwei Liu, Kelly J. Yu, Melvin L. K. Chua, Brigette B. Y. Ma, Ming Yuan Chen, Benjamin A. Pinsky, Pei-Jen Lou, John K. S. Woo, Wan-Lun Hsu, Julia Simon, Denise L. Doolan, Tim Waterboer, Edwin P. Hui, Hui Li, Raymond K. Tsang, Kenneth C. W. Wong, Julian P. Goh, Alexander C. Vlantis, Qi Yong Ai, Lun M. Wong, Victor Abdullah, Jin Ching Lin, Chien-Jen Chen, Ruth M. Pfeiffer, Quynh-Thu Le, Anne W. M. Lee, Mingfang Ji, Sumei Cao, Jun Ma, Anthony T. C. Chan, K. C. Allen Chan, Allan Hildesheim

Summary: A meeting of experts in November 2021 discussed the performance and cost-effectiveness of EBV-based approaches for screening early stage nasopharyngeal carcinoma. Both serum EBV antibody and plasma EBV DNA testing methods were found to be favorable. Additionally, the use of MRI was recommended to increase the sensitivity of NPC detection without greatly impacting the cost-effectiveness of the screening program.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy

Lili Li, Xing-sheng Shu, Hua Geng, Jianming Ying, Lei Guo, Jie Luo, Tingxiu Xiang, Longtao Wu, Brigette B. Y. Ma, Anthony T. C. Chan, Xiaofeng Zhu, Richard F. Ambinder, Qian Tao

Summary: Peptides/small proteins encoded by noncanonical open reading frames (ORF) of previously claimed non-coding RNAs have important biological functions but are largely uncharacterized. In this study, we identified and validated a small protein SP0495 as a novel tumor suppressor, frequently inactivated by promoter methylation in multiple tumors. SP0495 functions as a phosphoinositide-binding protein, regulating AKT signaling activation and autophagy. It inhibits tumor cell growth and induces apoptosis, cell cycle arrest, senescence, and autophagy through multiple mechanisms, including the modulation of phosphoinositides turnover and autophagic/proteasomal degradation of autophagy regulators. SP0495 has the potential to be a biomarker for cancer diagnosis and prognosis.

CELL DEATH AND DIFFERENTIATION (2023)

Add to Collection

Review Oncology

TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Benjamin P. Levy, Enriqueta Felip, Martin Reck, James C. H. Yang, Federico Cappuzzo, Yasuto Yoneshima, Caicun Zhou, Siddhartha Rawat, Jingdong Xie, Priyanka Basak, Lu Xu, Jacob Sands

Summary: The TROPION-Lung08 study is a Phase III trial evaluating the safety and efficacy of Dato-DXd plus pembrolizumab versus pembrolizumab monotherapy for advanced/metastatic NSCLC patients without AGAs and with PD-L1 tumor proportion score =50%. The primary endpoints are progression-free survival and overall survival, while secondary endpoints include objective response rate, duration of response, safety, and presence of antidrug antibodies.

FUTURE ONCOLOGY (2023)

Add to Collection

Article Oncology

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Domine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodriguez-Abreu

Summary: This study presents the 5-year outcomes of the KEYNOTE-189 study, which included previously untreated metastatic nonsquamous non-small-cell lung cancer patients. The results show that treatment with pembrolizumab plus pemetrexed-platinum significantly improves overall survival and progression-free survival compared to placebo plus pemetrexed-platinum. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care for previously untreated metastatic non-small-cell lung cancer patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs

Ze Zhou, Mary-Jane L. Ma, Rebecca W. Y. Chan, W. K. Jacky Lam, Wenlei Peng, Wanxia Gai, Xi Hu, Spencer C. Ding, Lu Ji, Qing Zhou, Peter P. H. Cheung, Stephanie C. Y. Yu, Jeremy Y. C. Teoh, Cheuk-Chun Szeto, John Wong, Vincent W. S. Wong, Grace L. H. Wong, Stephen L. Chan, Edwin P. Hui, Brigette B. Y. Ma, Anthony T. C. Chan, Rossa W. K. Chiu, K. C. Allen Chan, Y. M. Dennis Lo, Peiyong Jiang

Summary: Using a non-negative matrix factorization algorithm, this study identified distinct types of cfDNA cleavage patterns based on different end motifs. These profiles were associated with specific DNA nucleases and could be used to diagnose autoimmune disorders and cancer.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Add to Collection

Article Oncology

Frequency of Peripheral CD8+T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy

Shweta Mahajan, Hayri E. Balcioglu, Astrid Oostvogels, Willem A. Dik, K. C. Allen Chan, Kwok-Wai Lo, Edwin P. Hui, Anna Tsang, Joanna Tong, Wai Kei Jacky Lam, Kenneth Wong, Anthony T. C. Chan, Brigette B. Y. Ma, Reno Debets

Summary: Post-radiotherapy clearance of plasma EBV DNA is associated with prognosis in NPC patients. T cells, particularly CD8+ T cells expressing CCR1, 4 and/or 5, play a role in this clearance process. Differences in chemo-attractants related to T-cell chemotaxis are also linked to clinical outcome. Validation in larger cohorts is needed to confirm these findings.

CANCERS (2023)

Add to Collection

Article Medicine, General & Internal

Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial

Nancy Y. Lee, Jonathan Harris, John Kim, Adam Garden, James Mechalakos, David G. Pfister, Anthony T. C. Chan, Kenneth Hu, A. Dimitrios Colevas, Steven Frank, George Shenouda, Voichita Bar-Ad, John N. Waldron, Paul M. Harari, Adam Raben, Pedro Torres-Saavedra, Quynh-Thu Le

Summary: The study aimed to assess the long-term toxic effects and clinical outcomes associated with adding bevacizumab, a vascular endothelial growth factor inhibitor, to standard chemoradiation for patients with nasopharyngeal carcinoma (NPC). The results showed favorable long-term outcomes and no severe adverse events when using bevacizumab in combination with chemoradiation. Further investigation may be warranted.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Oncology

Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?

W. K. Jacky Lam, Anthony T. C. Chan

Summary: A recent study has identified a new serological biomarker for NPC screening that targets the EBV protein BNLF2b. This biomarker demonstrated higher sensitivity and specificity for NPC detection compared with conventional antibodies.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmana, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson

Summary: These analyses investigate the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the PARP inhibitor talazoparib in the ABRAZO trial. The study finds that BRCA mutations and HRD have a significant effect on the efficacy of talazoparib in germline BRCA1/2-mutation carriers. The presence of BRCA1/2 mutations and loss of heterozygosity at BRCA locus indicate HRD. Non-BRCA tumor mutations, such as TP53 and PIK3CA, are also associated with specific BRCA mutations.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Claire Petit, Anne Lee, Jun Ma, Benjamin Lacas, Wai Tong Ng, Anthony T. C. Chan, Ruey-Long Hong, Ming-Yuan Chen, Lei Chen, Wen-Fei Li, Pei-Yu Huang, Terence Tan, Roger K. C. Ngan, Guopei Zhu, Hai-Qiang Mai, Edwin P. Hui, George Fountzilas, Li Zhang, Alexandra Carmel, Dora L. W. Kwong, James Moon, Jean Bourhis, Anne Auperin, Jean-Pierre Pignon, Pierre Blanchard

Summary: This study updated the evaluation of chemotherapy for nasopharynx carcinoma through a network meta-analysis. The results showed that the addition of induction chemotherapy or adjuvant chemotherapy to chemoradiotherapy improved overall survival for patients with non-metastatic nasopharyngeal carcinoma compared to chemoradiotherapy alone.

LANCET ONCOLOGY (2023)

Add to Collection

Article Oncology

SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

Ana Beatriz Sanchez-Heras, Teresa Ramon y Cajal, Marta Pineda, Elena Aguirre, Begona Grana, Isabel Chirivella, Judit Balmana, Joan Brunet

Summary: Li-Fraumeni syndrome is caused by TP53 gene heterozygous germline pathogenic variants. It is associated with a high risk of various malignant tumors in childhood and adulthood, including premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The concept of SLF has expanded to hereditable TP53-related cancer syndrome (hTP53rc) due to the variability of clinical manifestations, which don't always meet the classic criteria of Li-Fraumeni syndrome. Prospective studies are needed to assess genotype-phenotype characteristics and risk-adjusted recommendations.

CLINICAL & TRANSLATIONAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma

D. C. T. Chan, W. K. J. Lam, E. P. Hui, B. B. Y. Ma, C. M. L. Chan, V. C. T. Lee, S. H. Cheng, W. Gai, P. Jiang, K. C. W. Wong, F. Mo, B. Zee, A. D. King, Q. T. Le, A. T. C. Chan, K. C. A. Chan, Y. M. D. Lo

Summary: Sequencing of plasma EBV DNA can enhance the accuracy of prognostication for nasopharyngeal carcinoma patients. It provides better prediction of local and distant recurrences through quantitative and size profiling analysis. It can also further define a subgroup of patients with undetectable EBV DNA on quantitative PCR, resulting in improved survival outcomes.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

The radiobiological effect of using Acuros XB vs anisotropic analytical algorithm on hepatocellular carcinoma stereotactic body radiation therapy

Michael L. M. Cheung, Monica W. K. Kan, Vanessa T. Y. Yeung, Darren M. C. Poon, Michael K. M. Kam, Louis K. Y. Lee, Anthony T. C. Chan

Summary: The purpose of this study was to investigate the radiobiological effect of using Acuros XB (AXB) vs Analytic Anisotropic Algorithm (AAA) in hepatocellular carcinoma (HCC) stereotactic body radiation therapy (SBRT). Different computational methods may have an impact on tumor control probability (TCP), normal tissue complication probability (NTCP), and uncomplicated tumor control probability (UTCP).

MEDICAL DOSIMETRY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.